AgingResearch.NewsJoin free

Usona Institute

CompanyUnited States

ROR

Usona Institute develops one asset, in phase 1 (Psilocybin in aging). Mostly small molecule acting on HTR2A; based in the United States.

1
Asset
Furthest stage
Phase 1
1
Trial
2
Signals

Pipeline

1

  • Psilocybin

    Converted to psilocin, which activates serotonin 5-HT2A receptors.

    Phase 1, Small molecule, HTR2A, aging, biomarkers of aging

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials3
  • Signals2
  • Similar companies6

Intelligence